The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ALMS | -61.27% | N/A | N/A | -65% |
| S&P | +18.13% | +110.72% | +16.08% | +26% |
Alumis, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. It focuses on building a pipeline of molecules with the potential to address a broad range of immune-mediated diseases such as monotherapy or combination therapies. The company was founded on January 29, 2021 and is headquartered in San Francisco, CA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.67M | 0.0% |
| Gross Profit | $1.80M | 336.3% |
| Gross Margin | 67.37% | 0.0% |
| Market Cap | $309.57M | 85.8% |
| Market Cap / Employee | $1.68M | 0.0% |
| Employees | 184 | 68.8% |
| Net Income | $59.32M | 205.0% |
| EBITDA | -$132.57M | -139.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $152.12M | -2.0% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $34.72M | 15.5% |
| Short Term Debt | $4.06M | 166.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -51.94% | 0.0% |
| Return On Invested Capital | -152.19% | 25.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$106.97M | -102.9% |
| Operating Free Cash Flow | -$106.35M | -103.4% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | -1.32 | 1.23 | 1.28 | 0.97 | -154.27% |
| Price to Sales | 19.17 | 11.46 | - | ||
| Price to Tangible Book Value | -1.32 | 1.23 | 1.28 | 0.97 | -154.27% |
| Enterprise Value to EBITDA | -2.56 | -1.74 | -1.68 | 1.64 | -107.69% |
| Return on Equity | -198.7% | -247.0% | -66.4% | - | |
| Total Debt | $31.10M | $30.72M | $31.88M | $38.78M | 22.81% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
